Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-12-08
DOI
10.3389/fendo.2020.00648
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma
- (2020) David C. Smith et al. INVESTIGATIONAL NEW DRUGS
- Long-acting pasireotide improves clinical signs and quality of life in Cushing’s disease: results from a phase III study
- (2020) A. Lacroix et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
- (2020) Jonathan Poirier et al. Cancers
- Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
- (2020) Rosario Pivonello et al. Lancet Diabetes & Endocrinology
- Osilodrostat is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing’s Syndrome: an in Vitro Study
- (2019) S G Creemers et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center
- (2019) C. Simeoli et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study
- (2019) Maria Fleseriu et al. Frontiers in Endocrinology
- Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study
- (2019) Luca Manetti et al. Pituitary
- Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial
- (2019) Maria Fleseriu et al. Lancet Diabetes & Endocrinology
- Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study
- (2019) Maria Fleseriu et al. CLINICAL ENDOCRINOLOGY
- Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
- (2019) André Lacroix et al. Pituitary
- Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis
- (2018) Leonie H. A. Broersen et al. Pituitary
- ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing’s syndrome
- (2018) Daniel K. Langlois et al. BMC Endocrine Disorders
- Advances in the medical treatment of Cushing's syndrome
- (2018) Richard A Feelders et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
- (2018) André Lacroix et al. Lancet Diabetes & Endocrinology
- Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysis
- (2018) R. Palui et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Dopamine Agonists for Pituitary Adenomas
- (2018) Odelia Cooper et al. Frontiers in Endocrinology
- Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells
- (2018) Federico Gatto et al. Pituitary
- DIAGNOSIS OF ENDOCRINE DISEASE: Differentiation of pathologic/neoplastic hypercortisolism (Cushing’s syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing’s syndrome)
- (2017) James W Findling et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist
- (2017) Hazel J. Hunt et al. JOURNAL OF MEDICINAL CHEMISTRY
- ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells andin vivo
- (2016) Yunhui Cheng et al. ENDOCRINE-RELATED CANCER
- ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs
- (2016) Christopher R. LaPensee et al. ENDOCRINOLOGY
- Cabergoline for Cushing’s disease: a large retrospective multicenter study
- (2016) A Ferriere et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A Single-Center 10-Year Experience with Pasireotide in Cushing’s Disease: Patients’ Characteristics and Outcome
- (2016) L. Trementino et al. HORMONE AND METABOLIC RESEARCH
- Complications of Cushing's syndrome: state of the art
- (2016) Rosario Pivonello et al. Lancet Diabetes & Endocrinology
- No Untoward Effect of Long-Term Ketoconazole Administration on Electrocardiographic QT Interval in Patients with Cushing's Disease
- (2015) Martina De Martin et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- The Treatment of Cushing's Disease
- (2015) Rosario Pivonello et al. ENDOCRINE REVIEWS
- Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients
- (2015) P. Burman et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- THERAPY OF ENDOCRINE DISEASE: Steroidogenesis enzyme inhibitors in Cushing's syndrome
- (2015) E. Daniel et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
- (2015) Hilal S. Khalil et al. JOURNAL OF BIOTECHNOLOGY
- Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
- (2015) Lynnette K. Nieman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients
- (2015) Eleni Daniel et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease
- (2015) Ning-Ai Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cushing's syndrome
- (2015) André Lacroix et al. LANCET
- Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease
- (2015) Maria Fleseriu et al. Pituitary
- Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEISMIC study and long-term extension
- (2015) Henry G. Fein et al. BMC Endocrine Disorders
- Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study
- (2014) Rosario Pivonello et al. CLINICAL ENDOCRINOLOGY
- Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease
- (2014) Susan M Webb et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Ketoconazole in Cushing's Disease: Is It Worth a Try?
- (2014) Frederic Castinetti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects
- (2014) Joël Ménard et al. Journal of Translational Medicine
- Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial
- (2014) Jochen Schopohl et al. Pituitary
- Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing's disease
- (2013) O. F. C. van den Bosch et al. CLINICAL ENDOCRINOLOGY
- Global clinical response in Cushing's syndrome patients treated with mifepristone
- (2013) Laurence Katznelson et al. CLINICAL ENDOCRINOLOGY
- Improvement in Insulin Sensitivity During Mifepristone Treatment of Cushing Syndrome:Early and Late Effects
- (2013) Amisha Wallia et al. DIABETES CARE
- LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study
- (2013) Xavier Bertagna et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?
- (2013) M. Barbot et al. Pituitary
- Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
- (2013) M. Boscaro et al. Pituitary
- Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors
- (2013) Erik L. Meredith et al. ACS Medicinal Chemistry Letters
- A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome
- (2012) Elena Valassi et al. CLINICAL ENDOCRINOLOGY
- Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers: A Single-Center, Open-Label, Ascending-Dose Study
- (2012) Stephan Petersenn et al. CLINICAL THERAPEUTICS
- Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study
- (2012) H. Dietrich et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
- (2012) Camille Baudry et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome
- (2012) Maria Fleseriu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Aldosterone synthase inhibition in humans
- (2012) Michel Azizi et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
- (2012) Annamaria Colao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma
- (2012) C. K. Cheng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
- (2012) Georg Golor et al. Drug Design Development and Therapy
- Mitotane has a strong and a durable inducing effect on CYP3A4 activity
- (2011) Nielka P van Erp et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome
- (2011) Peter Kamenický et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pasireotide (SOM230), a Novel Multireceptor-Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7-Day Subcutaneous Infusion in Healthy Male Volunteers
- (2011) Stephan Petersenn et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor
- (2011) N.-A. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy of Cabergoline in Uncured (Persistent or Recurrent) Cushing Disease After Pituitary Surgical Treatment with or without Radiotherapy
- (2010) Anurag Lila et al. Endocrine Practice
- Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
- (2010) Christophe Le Tourneau et al. EUROPEAN JOURNAL OF CANCER
- Cabergoline monotherapy in the long-term treatment of Cushing's disease
- (2010) Ariane Godbout et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Ketoconazole enantiomer for the treatment of diabetes mellitus
- (2010) Richard Arakaki et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- HORMONAL AND ELECTROLYTE RESPONSES TO THE ALDOSTERONE SYNTHASE INHIBITOR LCI699 IN SODIUM DEPLETED HEALTHY SUBJECTS
- (2010) Joël Menard et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease
- (2010) Richard A. Feelders et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Efficacy of Seliciclib in Combination with Ionizing Radiation for Human Nasopharyngeal Carcinoma
- (2009) A. B.Y. Hui et al. CLINICAL CANCER RESEARCH
- Merits and pitfalls of mifepristone in Cushing's syndrome
- (2009) F Castinetti et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease
- (2009) Lucio Vilar et al. Pituitary
- Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents
- (2008) I. N. Fleming et al. CLINICAL CANCER RESEARCH
- Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial
- (2008) M. Boscaro et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Medical Treatment of Cushing’s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery
- (2008) Rosario Pivonello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started